Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response

Publisher： Karger

E-ISSN： 1421-9662|136|1|45-51

ISSN： 0001-5792

Source： Acta Haematologica, Vol.136, Iss.1, 2016-05, pp. : 45-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead

By  

Acta Haematologica, Vol. 136, Iss. 1, 2016-05 ,pp. : 43-44

Karger

Access to resources Recommend Favorite

Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 364-373

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort

By  

Acta Haematologica, Vol. 130, Iss. 1, 2013-01 ,pp. : 16-22

Karger

Access to resources Recommend Favorite

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

By Wu Eric Q.   Johnson Scott   Beaulieu Nicolas   Arana Mateo   Bollu Vamsi   Guo Amy   Coombs John   Feng Weiwei   Cortes Jorge  

Current Medical Research and Opinion, Vol. 26, Iss. 1, 2010-01 ,pp. : 61-69

Informa Healthcare

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite